Tag: psa doubling time

Quick Search


After Local Treatments

Fri 30 Sep 2011

Introduction Local treatments are intended to eliminate cancer in (and sometimes around) the prostate. Recurrence may be due to cancer remaining in the prostate bed and/or tumors that are remote from that area. Evaluating Options For recurrence after local treatments, your decisions include: If your cancer is believed to be confined to the prostate bed,Read More ›

Immune Treatment for PSA-Relapsed Prostate Cancer

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 PSA-Relapsed prostate cancer can be effectively controlled with Testosterone Inactivating Pharmaceuticals (TIP). When TIP is started soon after relapse, remissions last an average of 11 years. However, TIP has notable side effects such as low libido, hot flashes, osteoporosis, muscle wasting and weight gain. Quality-of-life isRead More ›

PSA Doubling Time

Sun 31 Aug 2008

PSADT has been evaluated in patients with a rising PSA after local treatment with either RP or RT.1 In these settings, PSADT has been significantly shorter in patients who developed metastases, than in those who did not develop metastatic disease. For example, the mean PSADT in the RP and RT groups who developed metastatic diseaseRead More ›

What We Should Have Learned About Prostate Cancer (PC) in the Past 10 Years: Part Three

Sun 31 Aug 2008

  by Stephen B. Strum, MD, FACP Medical Oncologist and PCRI Co-founder Ashland, OR Edited from PCRI Insights August, 2008 v 11.3 In Part I and Part II of this series, I presented an in-depth discussion of key issues relating to the chemoprevention of PC, and I discussed in depth the results of the PCPTRead More ›

Using PSA Intelligently to Manage Prostate Cancer: Part 2 of 2

Wed 31 Aug 2005

PCRI Insights August, 2005 vol. 8, no. 3 By Jonathan McDermed, Pharm. D., Diagnostic Products Corporation Corollary to Part One In Part One of this article (Insights, August 2003), I reviewed studies that described differences in PSA levels between men who eventually developed, or did not develop, prostate cancer in later life. One of theseRead More ›

What Every Doctor Who Treats Male Patients Should Know

Tue 31 May 2005

PCRI Insights May, 2005 vol. 8, no. 2 Stephen B. Strum, MD, FACP, Medical Oncologist Specializing in Prostate Cancer and Donna Pogliano, Prostate Cancer Advocate Clinical Practice Prostate Cancer Diagnosis Guidelines Starting at forty years of age, every man should have an annual PSA (prostate-specific antigen) test and a DRE (digital rectal examination). Men atRead More ›

The PCRI Views Regarding Testing for Prostate Cancer Using PSA as a Principal Marker

Tue 31 Aug 2004

  PCRI Insights August 2004 vol. 7, no. 3 PCRI Statement on Annual Testing for PC (The Basics) The Prostate Cancer Research Institute (PCRI) strongly supports annual testing for the early detection of prostate cancer. Effective testing combines both a prostate specific antigen (PSA) blood test and a digital rectal exam (DRE) for men, beginningRead More ›

Using PSA Intelligently to Manage Prostate Cancer: Part 1 of 2

Sun 31 Aug 2003

Using PSA Intelligently to Manage Prostate Cancer, Part 1 of 2 PCRI Insights August, 2003 vol. 6, no. 3 By Jonathan McDermed, Pharm.D., Diagnostic Products Corporation PSA is the tumor marker of choice to aid in the diagnosis of prostate cancer (PC), to assess prognosis, and to monitor patients treated for this disease. Despite growingRead More ›

A Strategy of Success in the Treatment of Prostate Cancer – 2

Wed 31 Jul 2002

PCRI Insights July, 2002 vol. 5, no. 1 By Stephen B. Strum, MD, FACP Page <<  1  2  3  >> The PSA and PSA Dynamics The absolute values of PSA, the changes in PSA over time, factors associated with PSA increases, and the volume of the prostate gland itself are some of the issues thatRead More ›